CRL-40,940 (also known as flmodafinil, bisfluoromodafinil and lauflumide) is the bisfluoro
analog of
modafinil.[1][2][3][4][5] It is a
eugeroic as well as a weak
dopamine reuptake inhibitor. Its inventors claim that it is more effective than modafinil and adrafinil, with fewer side effects. It was patented in 2013, and pre-clinical trials have been underway since December 2015.[6]
^US 20130295196, Konofal E, "Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof", published 7 November 2013